Nome et al. measured 17 serum inflammatory biomarkers in breast cancer patients who received chemotherapy at different time points in a phase II randomized clinical trial and obtained results that support PTX-3 as proangiogenic factor [58]. Here, PTX3 is linked to breast carcinoma.